Kestra Medical Technologies, Ltd. Earnings Summary — Q4 2026

• Revenue for Q4 2026 reached $28.64 million, representing a robust 66% year-over-year increase, driven by the commercial ramp of the ASSURE system.
• Net losses widened to $38.84 million for the quarter, reflecting the high costs of capturing market share and scaling commercial infrastructure.
• Gross margins showed sequential improvement, rising to 54.76% in Q4 from 52.57% in Q3, suggesting better manufacturing efficiency as volumes grow.
• Operating expenses surged to $55.03 million, primarily dominated by SG&A spending to penetrate the cardiac monitoring market.
• The company's share count increased significantly year-over-year to 58 million shares, indicating substantial equity dilution to fund operations.
• Free cash flow burn remains high at -$28.38 million for the quarter, highlighting a continued dependence on external capital.

Management is focused on challenging the incumbent monopoly in the WCD market through technological differentiation and patient compliance. While specific quantitative guidance was not provided, the operational focus remains on commercializing the ASSURE system and navigating the US reimbursement landscape.

Improving

While losses are substantial, the dramatic improvement in revenue and gross margins relative to the prior year suggests commercial traction is beginning to offset some scale-up costs.

Kestra is in a high-growth, early-commercialization phase. The narrowing of operating margin percentages indicates some efficiency gains, but the path to profitability remains long given the current heavy spend on SG&A and R&D.